190 related articles for article (PubMed ID: 37511490)
1. TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma.
Amin N; Wang H; Song Q; Bhaskar M; Yadav SP; Gilbert MR; Pant H; Tabouret E; Zhuang Z
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511490
[TBL] [Abstract][Full Text] [Related]
2. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma.
Tabouret E; Wang H; Amin N; Jung J; Appay R; Cui J; Song Q; Cardone A; Park DM; Gilbert MR; Pant H; Zhuang Z
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708903
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of TP5, a Cdk5/p25 inhibitor, in
Tran J; Taylor SKB; Gupta A; Amin N; Pant H; Gupta BP; Mishra RK
Curr Res Neurobiol; 2021; 2():100006. PubMed ID: 36246507
[TBL] [Abstract][Full Text] [Related]
4. TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease.
Binukumar BK; Pant HC
Neural Regen Res; 2016 May; 11(5):698-701. PubMed ID: 27335538
[TBL] [Abstract][Full Text] [Related]
5. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
Davis SL; Hartman SJ; Bagby SM; Schlaepfer M; Yacob BW; Tse T; Simmons DM; Diamond JR; Lieu CH; Leal AD; Cadogan EB; Hughes GD; Durant ST; Messersmith WA; Pitts TM
BMC Cancer; 2022 Oct; 22(1):1107. PubMed ID: 36309653
[TBL] [Abstract][Full Text] [Related]
6. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.
Ehrlich SM; Liebl J; Ardelt MA; Lehr T; De Toni EN; Mayr D; Brandl L; Kirchner T; Zahler S; Gerbes AL; Vollmar AM
J Hepatol; 2015 Jul; 63(1):102-13. PubMed ID: 25660209
[TBL] [Abstract][Full Text] [Related]
7. Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury.
Yousuf MA; Tan C; Torres-Altoro MI; Lu FM; Plautz E; Zhang S; Takahashi M; Hernandez A; Kernie SG; Plattner F; Bibb JA
J Neurochem; 2016 Jul; 138(2):317-27. PubMed ID: 26998748
[TBL] [Abstract][Full Text] [Related]
8. Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.
Binukumar BK; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
Mol Biol Cell; 2015 Dec; 26(24):4478-91. PubMed ID: 26399293
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Hong YS; Hong SW; Kim SM; Jin DH; Shin JS; Yoon DH; Kim KP; Lee JL; Heo DS; Lee JS; Kim TW
Int J Oncol; 2012 Jul; 41(1):76-82. PubMed ID: 22552540
[TBL] [Abstract][Full Text] [Related]
10. MHY451 induces cell cycle arrest and apoptosis by ROS generation in HCT116 human colorectal cancer cells.
Hwang NL; Kang YJ; Sung B; Hwang SY; Jang JY; Oh HJ; Ahn YR; Kim DH; Kim SJ; Ullah S; Hossain MA; Moon HR; Chung HY; Kim ND
Oncol Rep; 2017 Sep; 38(3):1783-1789. PubMed ID: 28731136
[TBL] [Abstract][Full Text] [Related]
11. Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells.
Huang CI; Huang YK; Lee HM; Chen JH; Su YC; Lin PM
Anticancer Res; 2023 May; 43(5):1933-1941. PubMed ID: 37097665
[TBL] [Abstract][Full Text] [Related]
12. p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.
Zhang L; Liu W; Szumlinski KK; Lew J
Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20041-6. PubMed ID: 23151508
[TBL] [Abstract][Full Text] [Related]
13. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
[TBL] [Abstract][Full Text] [Related]
14. SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.
Xia Y; Lei Q; Zhu Y; Ye T; Wang N; Li G; Shi X; Liu Y; Shao B; Yin T; Zhao L; Wu W; Song X; Xiong Y; Wei Y; Yu L
Cancer Lett; 2014 Dec; 355(2):297-309. PubMed ID: 25301449
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
16. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
Zhang S; Lu Z; Mao W; Ahmed AA; Yang H; Zhou J; Jennings N; Rodriguez-Aguayo C; Lopez-Berestein G; Miranda R; Qiao W; Baladandayuthapani V; Li Z; Sood AK; Liu J; Le XF; Bast RC
PLoS One; 2015; 10(7):e0131833. PubMed ID: 26146988
[TBL] [Abstract][Full Text] [Related]
17. Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer.
Yoon S; Lee BK; Kim KP
Phytomedicine; 2023 Dec; 121():155120. PubMed ID: 37806154
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer.
Wu MM; Zhang Z; Tong CWS; Yan VW; Cho WCS; To KKW
Life Sci; 2020 Dec; 262():118522. PubMed ID: 33011217
[TBL] [Abstract][Full Text] [Related]
19. CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis.
Zhuang K; Zhang J; Xiong M; Wang X; Luo X; Han L; Meng Y; Zhang Y; Liao W; Liu S
Cell Death Dis; 2016 Oct; 7(10):e2415. PubMed ID: 27735944
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
